Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COLUMN
COLUMN
-
Expat Truths from the Japanese Medical Device World
December 3, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Finding Captains in Your Organization
October 12, 2018
-
Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
-
How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
-
Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
-
5 Billion Yen Blockbuster?
June 20, 2018
-
It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
-
Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
-
When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
-
What to Do about the Feeling of Torschlusspanik?
October 27, 2017
-
Women! Rock the Boat and Get Promoted
September 22, 2017
-
Getting the Right Message
August 25, 2017
-
Putting on Your Pants
July 21, 2017
-
Reputable Combination
July 11, 2017
-
What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
-
Doubling Down on Digital
May 26, 2017
-
Global Opportunities for Global Minds
April 21, 2017
-
Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…